0000000000925710

AUTHOR

Arie Figer

showing 1 related works from this author

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal canc…

2009

Abstract Background: Second-line irinotecan-based chemotherapy is commonly used in metastatic colorectal cancers after first-line oxaliplatin-based chemotherapy. No standard schedule of irinotecan has been established in this situation. Patients and methods: Metastatic colorectal cancer patients included in the OPTIMOX1 phase III study received first-line oxaliplatin-based chemotherapy (FOLFOX). No second line was defined in the protocol, but data concerning second line were prospectively registered. Inclusion criterion was patients receiving an irinotecan-based second-line chemotherapy. Second-line progression-free survival (PFS) and tumor response were evaluated according to type of irino…

MaleOncologymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentLeucovorinIrinotecanBolus (medicine)FOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTreatment FailureneoplasmsChemotherapybusiness.industryHematologyMiddle Agedmedicine.diseasedigestive system diseasesOxaliplatinOxaliplatinIrinotecanRegimenTreatment OutcomeOncologyFOLFIRICamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct